Development of antibody to hepatitis C virus (HCV) in acute and chronic non-A, non-B post-transfusion hepatitis

G. Pastore, L. Monno, M. Milella, T. Santantonio, M. G. Rumi, M. Colombo, A. Giannelli, C. Fico, G. De Stasio, A. Lattanzio, M. De Ruvo, E. Sforza

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

The antibody to hepatitis C virus (anti-HCV) was measured by an immunoassay in 507 serum samples from 94 patients with acute and chronic post-transfusion non-A, non-B hepatitis (NANB) and in 436 healthy blood donors. Anti-HCV was found in 70.8 of patients with acute hepatitis, in 78.2 with chronic hepatitis, and in 1.4 of healthy blood donors. In acute hepatitis, anti-HCV appeared in the serum from 4 to 34 weeks after transfusion and from 1 to 30 weeks after the onset of the overt disease. Three patients with resolving hepatitis (21%) and 2 who developed chronic hepatitis (10%) lost anti-HCV during a mean follow-up period of 28 months. Among the 36 patients with chronic hepatitis, 2 (6%) lost anti-HCV after 12 months and 8 years respectively. These data indicate that in recent years HCV has been the major etiologic agent of acute and chronic transfusion-associated hepatitis (TAH) in our geographical area. The late appearance of anti-HCV from the onset of clinical and biochemical signs of acute hepatitis in more than 70% of patients limits the diagnostic utility of this assay for an earlier serological diagnosis of acute NANB hepatitis. Additional studies are required to determine the diagnostic significance of this antibody in chronic NANB hepatitis.

Original languageEnglish
Pages (from-to)580-584
Number of pages5
JournalEuropean Journal of Epidemiology
Volume8
Issue number4
DOIs
Publication statusPublished - Jul 1992

Fingerprint

Hepatitis C Antibodies
Hepatitis
Chronic Hepatitis
Blood Donors
Hepacivirus
Serum
Immunoassay
Early Diagnosis

Keywords

  • HCV
  • NANB hepatitis
  • TAH

ASJC Scopus subject areas

  • Epidemiology

Cite this

Development of antibody to hepatitis C virus (HCV) in acute and chronic non-A, non-B post-transfusion hepatitis. / Pastore, G.; Monno, L.; Milella, M.; Santantonio, T.; Rumi, M. G.; Colombo, M.; Giannelli, A.; Fico, C.; De Stasio, G.; Lattanzio, A.; De Ruvo, M.; Sforza, E.

In: European Journal of Epidemiology, Vol. 8, No. 4, 07.1992, p. 580-584.

Research output: Contribution to journalArticle

Pastore, G, Monno, L, Milella, M, Santantonio, T, Rumi, MG, Colombo, M, Giannelli, A, Fico, C, De Stasio, G, Lattanzio, A, De Ruvo, M & Sforza, E 1992, 'Development of antibody to hepatitis C virus (HCV) in acute and chronic non-A, non-B post-transfusion hepatitis', European Journal of Epidemiology, vol. 8, no. 4, pp. 580-584. https://doi.org/10.1007/BF00146380
Pastore, G. ; Monno, L. ; Milella, M. ; Santantonio, T. ; Rumi, M. G. ; Colombo, M. ; Giannelli, A. ; Fico, C. ; De Stasio, G. ; Lattanzio, A. ; De Ruvo, M. ; Sforza, E. / Development of antibody to hepatitis C virus (HCV) in acute and chronic non-A, non-B post-transfusion hepatitis. In: European Journal of Epidemiology. 1992 ; Vol. 8, No. 4. pp. 580-584.
@article{a3dfa8048e4548c1a515fe91d4d4dd0b,
title = "Development of antibody to hepatitis C virus (HCV) in acute and chronic non-A, non-B post-transfusion hepatitis",
abstract = "The antibody to hepatitis C virus (anti-HCV) was measured by an immunoassay in 507 serum samples from 94 patients with acute and chronic post-transfusion non-A, non-B hepatitis (NANB) and in 436 healthy blood donors. Anti-HCV was found in 70.8 of patients with acute hepatitis, in 78.2 with chronic hepatitis, and in 1.4 of healthy blood donors. In acute hepatitis, anti-HCV appeared in the serum from 4 to 34 weeks after transfusion and from 1 to 30 weeks after the onset of the overt disease. Three patients with resolving hepatitis (21{\%}) and 2 who developed chronic hepatitis (10{\%}) lost anti-HCV during a mean follow-up period of 28 months. Among the 36 patients with chronic hepatitis, 2 (6{\%}) lost anti-HCV after 12 months and 8 years respectively. These data indicate that in recent years HCV has been the major etiologic agent of acute and chronic transfusion-associated hepatitis (TAH) in our geographical area. The late appearance of anti-HCV from the onset of clinical and biochemical signs of acute hepatitis in more than 70{\%} of patients limits the diagnostic utility of this assay for an earlier serological diagnosis of acute NANB hepatitis. Additional studies are required to determine the diagnostic significance of this antibody in chronic NANB hepatitis.",
keywords = "HCV, NANB hepatitis, TAH",
author = "G. Pastore and L. Monno and M. Milella and T. Santantonio and Rumi, {M. G.} and M. Colombo and A. Giannelli and C. Fico and {De Stasio}, G. and A. Lattanzio and {De Ruvo}, M. and E. Sforza",
year = "1992",
month = "7",
doi = "10.1007/BF00146380",
language = "English",
volume = "8",
pages = "580--584",
journal = "European Journal of Epidemiology",
issn = "0393-2990",
publisher = "Springer Netherlands",
number = "4",

}

TY - JOUR

T1 - Development of antibody to hepatitis C virus (HCV) in acute and chronic non-A, non-B post-transfusion hepatitis

AU - Pastore, G.

AU - Monno, L.

AU - Milella, M.

AU - Santantonio, T.

AU - Rumi, M. G.

AU - Colombo, M.

AU - Giannelli, A.

AU - Fico, C.

AU - De Stasio, G.

AU - Lattanzio, A.

AU - De Ruvo, M.

AU - Sforza, E.

PY - 1992/7

Y1 - 1992/7

N2 - The antibody to hepatitis C virus (anti-HCV) was measured by an immunoassay in 507 serum samples from 94 patients with acute and chronic post-transfusion non-A, non-B hepatitis (NANB) and in 436 healthy blood donors. Anti-HCV was found in 70.8 of patients with acute hepatitis, in 78.2 with chronic hepatitis, and in 1.4 of healthy blood donors. In acute hepatitis, anti-HCV appeared in the serum from 4 to 34 weeks after transfusion and from 1 to 30 weeks after the onset of the overt disease. Three patients with resolving hepatitis (21%) and 2 who developed chronic hepatitis (10%) lost anti-HCV during a mean follow-up period of 28 months. Among the 36 patients with chronic hepatitis, 2 (6%) lost anti-HCV after 12 months and 8 years respectively. These data indicate that in recent years HCV has been the major etiologic agent of acute and chronic transfusion-associated hepatitis (TAH) in our geographical area. The late appearance of anti-HCV from the onset of clinical and biochemical signs of acute hepatitis in more than 70% of patients limits the diagnostic utility of this assay for an earlier serological diagnosis of acute NANB hepatitis. Additional studies are required to determine the diagnostic significance of this antibody in chronic NANB hepatitis.

AB - The antibody to hepatitis C virus (anti-HCV) was measured by an immunoassay in 507 serum samples from 94 patients with acute and chronic post-transfusion non-A, non-B hepatitis (NANB) and in 436 healthy blood donors. Anti-HCV was found in 70.8 of patients with acute hepatitis, in 78.2 with chronic hepatitis, and in 1.4 of healthy blood donors. In acute hepatitis, anti-HCV appeared in the serum from 4 to 34 weeks after transfusion and from 1 to 30 weeks after the onset of the overt disease. Three patients with resolving hepatitis (21%) and 2 who developed chronic hepatitis (10%) lost anti-HCV during a mean follow-up period of 28 months. Among the 36 patients with chronic hepatitis, 2 (6%) lost anti-HCV after 12 months and 8 years respectively. These data indicate that in recent years HCV has been the major etiologic agent of acute and chronic transfusion-associated hepatitis (TAH) in our geographical area. The late appearance of anti-HCV from the onset of clinical and biochemical signs of acute hepatitis in more than 70% of patients limits the diagnostic utility of this assay for an earlier serological diagnosis of acute NANB hepatitis. Additional studies are required to determine the diagnostic significance of this antibody in chronic NANB hepatitis.

KW - HCV

KW - NANB hepatitis

KW - TAH

UR - http://www.scopus.com/inward/record.url?scp=0026802217&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026802217&partnerID=8YFLogxK

U2 - 10.1007/BF00146380

DO - 10.1007/BF00146380

M3 - Article

C2 - 1327865

AN - SCOPUS:0026802217

VL - 8

SP - 580

EP - 584

JO - European Journal of Epidemiology

JF - European Journal of Epidemiology

SN - 0393-2990

IS - 4

ER -